PharmAust (ASX: PAA) progresses flagship Monepantel drug in treating canine lymphoma and COVID-19 (w/ Roger Aston)

Small Caps - A podcast by Small Caps

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

PharmAust (ASX: PAA) executive chairman and CEO Dr Roger Aston joins Small Caps to discuss the company's Monepantel drug and its antiviral potential after laboratory results have consistently shown it can interfere with the proliferation of SARS-CoV2, the virus causing COVID-19. More advanced trials for Monepantel are also underway, where it is being used to treat canine lymphoma. This phase IIb trial is evaluating Monepantel in treatment-naïve B cell lymphoma, with this study still recruiting and progressing.